KORU Medical Systems Inc (KRMD) FinancialsKRMDFinancialKORU Medical Systems Inc

KORU Medical Systems Inc (KRMD) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Domestic Core, accounting for 66.2% of total sales, equivalent to $7.98M. Other significant revenue streams include International Core and Pharma services and clinical traials. Understanding this composition is critical for investors evaluating how KRMD navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, KORU Medical Systems Inc maintains a gross margin of 63.39%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 5.21%, while the net margin is 2.10%. These profitability ratios, combined with a Return on Equity (ROE) of -10.52%, provide a clear picture of how effectively KRMD converts its operational activities into shareholder value.

In the context of the broader market, KRMD competes directly with industry leaders such as NYXH and INGN. With a market capitalization of $156.98M, it holds a significant position in the sector. When comparing efficiency, KRMD's gross margin of 63.39% stands against NYXH's 59.73% and INGN's 45.51%. Such benchmarking helps identify whether KORU Medical Systems Inc is trading at a premium or discount relative to its financial performance.

KORU Medical reported Q2 2026 revenue of $12.05 million, a 22% year-over-year increase, with a gross margin of 63.39%. However, the company has been operating at a loss, with a net income of $252,449 in Q2 2026 after several quarters of losses.